Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ Disease
source: Clinical Thyroidology
year: 2018
summary/abstract:Over-activity of the thyroid gland, called hyperthyroidism, can sometimes be caused by a flaw in a person’s immune system (the body’s natural defense system against infection). This problem is a type of autoimmune disorder called Graves’ disease. In addition to thyroid gland over-activity, Graves’ disease causes eye problems in some people, including eye bulging, loss of color vision, double vision, eye pain and dry eyes.
Not everyone diagnosed with Graves’ disease will develop eye problems. Identifying people diagnosed with Graves’ disease who do develop eye disease is important, however, because early treatment may make these eye problems less severe. The goal of this study is to identify which people diagnosed with Graves’ disease will eventually have eye problems. Such people could then be treated for these eye problems before these problems become severe, and possibly irreversible.
read more
myBinderRelated Content
-
Gut Microbes May Play Role in Graves ’ Disease Diagnosis, Thyroid AutoimmunityThe abundance and diversity of intestina...
-
Rehabilitative Orbital Decompression for Graves’ Orbitopathy: Results of a Randomized Clinical TrialPurpose: Orbital decompression (OD) is ...
-
Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid eye D...Thyroid eye disease is a disabling autoi...
-
Early Diagnosis of Thyroid Eye Disease (TED)Early Symptoms TED can first present wi...
-
Efficacy and Safety of Mycophenolate Mofetil in Patients With Active Moderate-to-Severe Graves’ OrbitopathyContext: Graves' orbitopathy (GO) is a ...
-
Smoking was Associated With Poor Response to Intravenous Steroids Therapy in Graves’ OphthalmopathyBackground: Previous studies have shown...
-
Prospective, Systematically Recorded Mycophenolate Safety Data in Graves’ OrbitopathyContext: The antiproliferative mechanis...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google